Welcome to our dedicated page for Seer SEC filings (Ticker: SEER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Seer, Inc.'s SEC filings document material events, operating results, securityholder rights and governance matters for a Nasdaq-listed life sciences company focused on research-use proteomics. Recent 8-K reports cover results of operations and financial condition, material definitive agreements, modifications to securityholder rights, other events and related exhibits.
The filings disclose Seer's Class A common stock, Preferred Stock Purchase Rights, Tax Benefit Preservation Plan for net operating loss and other tax attributes, amendments to that plan, and the completed conversion of Class B common stock into Class A common stock. They also record board and shareholder matters, leadership appointments, and intellectual-property updates related to the Proteograph Product Suite and particle-based protein enrichment.
Seer, Inc. reported that its Board of Directors unanimously rejected a revised unsolicited, non-binding proposal from the Radoff-JEC Group to acquire all outstanding Class A common stock for $2.35 per share in cash plus a contingent value right.
The Board, after consulting independent financial and legal advisors, determined the proposal significantly undervalues Seer, noting that the implied equity value is below the company’s current cash, cash equivalents and investments and does not reflect the value of its proteomics platform or growth prospects.
Seer highlights adoption of its Proteograph Product Suite, selection for Singapore’s SGK100 study, more than 80 peer-reviewed publications, and 240 worldwide patents (including 82 issued) as evidence of its strategic position. The company also disclosed it will file a definitive proxy statement and send a BLUE proxy card for its 2026 Annual Meeting.
Seer, Inc.: Activist group files preliminary proxy materials and an acquisition proposal. Bradley L. Radoff, Michael Torok and affiliated participants (the "Radoff-JEC Group") say they own approximately 7.6% of Seer and intend to solicit votes for director nominees at the 2026 annual meeting using a white universal proxy card.
The group submitted an improved non-binding proposal to acquire 100% of Seer for $2.35 per share in cash plus a contingent value right (CVR) giving stockholders a share of future proceeds from dispositions. The proposal cites a 39% premium to an unaffected closing price and is conditioned on at least $215 million of net cash at closing; it requests a Board response by May 2, 2026.
Seer, Inc. disclosed that it has received a highly contingent, non-binding and unsolicited proposal from the Radoff-JEC Group to acquire all outstanding shares of Seer’s Class A common stock for $2.25 per share in cash plus a contingent value right. The Board, with independent financial and legal advisors, will carefully review the proposal to decide what is in the best interests of the company and its stockholders. In parallel, the Radoff-JEC Group has nominated three director candidates for election at Seer’s 2026 Annual Meeting. Seer’s Corporate Governance and Nominating Committee will evaluate these nominees under the company’s bylaws, and the Board will provide its recommendation in a future definitive proxy statement. The company emphasized that no stockholder action is required at this time and plans to send a BLUE proxy card with its 2026 proxy materials.
Seer, Inc. received an amended Schedule 13D from a group led by Bradley Radoff and Michael Torok outlining an unsolicited takeover proposal and board contest. The group and related entities report beneficial ownership stakes ranging from 0.4% to 4.6% of Seer’s Class A common stock.
On April 13, 2026, the reporting persons submitted a non-binding proposal to acquire 100% of Seer’s equity for $2.25 per share in cash, a stated 33% premium to the most recent closing price, plus a contingent value right giving stockholders 80% of net proceeds from any sale or license of Seer’s business and assets, including PrognomiQ. The proposal assumes at least $215 million of net cash and cash equivalents at closing and is not subject to financing conditions.
The group asked Seer’s board to respond to the proposal by 5:00 p.m. ET on April 22, 2026, after which it would expire. Radoff also nominated Howard H. Berman, Joshua S. Horowitz and Luis E. Rinaldini to Seer’s board for the 2026 annual meeting and the group entered into an amended and restated group agreement covering joint filings, proxy solicitation efforts and trading restrictions while Seer’s tax benefit preservation plan (the “NOL Pill”) remains in effect.
Seer, Inc. reported that the U.S. Patent Trial and Appeal Board issued a Final Written Decision in an inter partes review of U.S. Patent No. 11,435,360 B2 covering Seer’s nanoparticle-based protein enrichment technology for its Proteograph product suite.
The PTAB found that petitioners PreOmics GmbH and Biognosys AG failed to show unpatentability of certain challenged claims, leaving a total of 23 patent claims, including five challenged and 18 unchallenged, valid and enforceable. Other challenged claims were found unpatentable. The upheld claims relate to detecting proteins across a wide concentration range and to particle aspects of the technology, which support deep proteomic analysis. Either side may appeal by filing a notice of appeal by May 25, 2026.
Seer, Inc. amended its Tax Benefit Preservation Plan to clarify the definition of “Beneficial Ownership” and its interaction with Treasury Regulation § 1.382-3(a)(1). The change follows a Delaware Court of Chancery stockholder action challenging the original definition. To resolve the matter and moot the claims, Seer agreed to this amendment and to pay plaintiff’s counsel a $250,000 mootness fee, which will fully satisfy any related claims for attorneys’ fees, costs, and expenses.
Seer, Inc. investors led by Bradley Radoff and Michael Torok have updated their Schedule 13D to detail a significant activist stake and challenge a new tax benefits preservation plan. The group now reports beneficial ownership of 4,277,528 Class A shares, representing approximately 7.6% of Seer’s 56,219,599 shares outstanding as of December 31, 2025.
The filing breaks out ownership across several entities. Bradley Radoff is deemed to beneficially own 2,610,232 shares, or about 4.6% of the company, including 500,000 shares held by the Radoff Family Foundation. Michael Torok is deemed to beneficially own 1,667,296 shares, or about 3.0%, including shares held through JEC II Associates, LLC and The MOS Trust.
The investors express strong concern with the board’s adoption of a tax benefits preservation plan on February 26, 2026, which limits additional ownership to 4.9%. They argue this measure may discourage shareholders from building larger positions in advance of any potential proxy contest and call on the board to justify the plan’s necessity and impact on stockholder rights.
Seer, Inc. files its annual report describing a fast-growing proteomics tools business built around its Proteograph Product Suite. The platform combines proprietary nanoparticles, automation (the SP200 instrument) and cloud software to deliver deep, unbiased proteomic data at peptide-level resolution.
In 2025 Seer launched its next-generation Proteograph ONE assay and SP200 automation, boosting throughput roughly tenfold versus its original assay to more than 1,000 samples per week. The company reports more than 190 customers in over 20 countries and cites around 70 third-party publications using its technology as of December 31, 2025.
Seer targets a roughly $30 billion proteomics market and positions its data-rich workflows as a foundation for population-scale studies and AI-driven biology. As of June 30, 2025, non-affiliate equity market value was about $113.8 million, and 56,420,772 Class A shares were outstanding as of February 23, 2026.